Home > Neurology > EAN 2019 > Multiple Sclerosis > Promising results of novel NMOSD treatments

Promising results of novel NMOSD treatments

EAN 2019
There are as yet no registered treatments for neuromyelitis optica spectrum disorders (NMOSD), but that will change soon. Three monoclonal antibodies –inebilizumab, satralizumab, and eculizumab– submitted promising safety and efficacy results in terms of relapse prevention in the past year. At the EAN 2019, efficacy and safety results of inebilizumab and satralizumab were presented [1,2]. Inebilizumab, an anti-CD19 monoclonal antibody, reduced attacks, disability progression, hospitalisations, and new lesions in NMOSD compared with placebo in the randomised controlled period of the N-MOmentum pivotal study [1]. The drug was well-tolerated, with adverse event (AE) rates similar to placebo. A total of 230 patients were randomised to inebilizumab (n=174) or placebo (n=56) monotherapy for 6.5 months. Of those, 91% were aquaporin 4-IgG seropositive (AQP4-IgG+). Study recruitment was stopped early because of clear evidence of efficacy. Inebilizumab reduced the r...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on